Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 901 - 925 of 14638 in total

Erlotinib

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... , which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Miglitol

Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start...
Approved
Matched Description: … amount of poly and oligosaccharides in the diet. ... Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the ... glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and …
Matched Categories: … Alimentary Tract and Metabolism …

Metixene

Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Approved

Troglitazone

Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … It was superseded by [pioglitazone] and [rosiglitazone]. …
Matched Categories: … Alimentary Tract and Metabolism …

Reslizumab

Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and promote programmed cell death [A31578]. ... , activation, and survival of eosinophils [FDA Label]. ... for recurrent exacerbation and asthma-related hospitalizations [A31579]. …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Tivozanib

Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Description: … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Faricimab

Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and ... retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization ... many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely target VEGF-A. …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Ubrogepant

Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and ... [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and …

Clonazepam

A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being...
Approved
Illicit
Matched Description: … benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and ... , however, like most benzodiazepines, clonazepam use has also been associated with recreational use and ... [FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …

Aluminum chloride

Aluminum chloride is a chemical compound with the chemical formula AlCl3. When contaminated with iron chloride, it often displays a yellow color compared to the white pure compound. It is used in various chemical applications as a Lewis base, with anhydrous aluminium trichloride being the most commonly used Lewis acid....
Approved
Investigational
Matched Categories: … Astringents and Deodorants …

Dabrafenib

Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Mexiletine

Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Approved
Investigational

Flunarizine

Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Approved
Matched Description: … peripheral origin, and as an adjuvant in the therapy of epilepsy. ... Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 ... effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and …
Matched Categories: … Calcium-Regulating Hormones and Agents …

Cobimetinib

Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Description: … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated ... It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of ... protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Flutemetamol (18F)

Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Approved
Investigational
Matched Categories: … Indicators and Reagents …

Tyrothricin

Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus . This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1,...
Approved
Matched Description: … Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus ... Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and ... other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Sevelamer

Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Approved
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …

Ezogabine

Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and …

Mitapivat

Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red...
Approved
Investigational
Matched Description: … alpha- and beta-thalassemia. ... other hereditary red blood cell disorders associated with hemolytic anemia, such as sickle cell disease and …
Matched Categories: … Blood and Blood Forming Organs ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Cocaine

An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of...
Approved
Illicit
Matched Description: … the eye, ear, nose, and throat. ... It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in ... It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse …
Matched Categories: … Analgesics and Anesthetics …

Nomifensine

Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … Also withdrawn from the Canadian and UK markets. …

Isradipine

Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity...
Approved
Investigational
Matched Description: … Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into ... It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel ... cardiac and arterial smooth muscle cells. …
Matched Categories: … Calcium-Regulating Hormones and Agents …

Chlorambucil

A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Approved
Matched Description: … nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Iron sucrose

Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron...
Approved
Matched Description: … chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …

Resmetirom

Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. …
Displaying drugs 901 - 925 of 14638 in total